Trilogy Capital’s Celgene Corp CELG Stock Holding History

Trilogy Capital’s Portfolio CELG Stock Details CELG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-24	Closed	-$2K	–	659
2018 Q3	$2K	Hold	24	–	–	﹤0.01%	530
2018 Q2	$2K	Sell	24 -40	-63%	-$3.32K	﹤0.01%	490
2018 Q1	$6K	Buy	+64	New	+$6.14K	﹤0.01%	306

Other funds holding CELG

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Trilogy Capital's CELG Position: Q4 2018 in Review

Trilogy Capital sold out of Celgene Corp (CELG) in Q4 2018, closing a stake of 24 shares — an estimated $2K sold.

Trilogy Capital first reported a position in CELG in Q1 2018 and held it in 3 quarters. The position peaked at $6K in Q1 2018. 1,317 funds tracked by Wall St. Rank hold CELG as of Q4 2018.

Trilogy Capital reported no remaining Celgene Corp position as of Q4 2018 after selling out during the quarter.
Trilogy Capital sold 24 Celgene Corp shares in Q4 2018, an estimated $2K.
Trilogy Capital first reported a position in Celgene Corp in Q1 2018 and held it in 3 quarters.
Trilogy Capital's Celgene Corp position peaked at $6K in Q1 2018.
1,317 funds tracked by Wall St. Rank held Celgene Corp as of Q4 2018.

Based on Trilogy Capital's 13F filing for Q4 2018, filed 15 Jan 2019.